Re: Numbers needed to harm
We thank the author of the recent rapid response for their interest in our study and for the comment regarding the use of the number needed to treat to harm.
The objective of our study was to determine the relationship between kidney function (assessed as different stages of chronic kidney disease) and the rate of major bleeding (i.e. safety of warfarin therapy) in older adults with atrial fibrillation, specifically in those commencing warfarin therapy. We focused on assessing the risk of major bleeding in this patient group as arguably, the reluctance of warfarin use in patients with chronic kidney disease and atrial fibrillation is largely in relation to uncertainties regarding their safety in this setting and there was limited data assessing this at different stages of chronic kidney disease in the literature. As such, the “control” group (i.e. “non-exposed” group in the treatment exposure sense of the term) used for the calculation of the number needed to treat to harm in our study was the non-chronic kidney disease group (defined as eGFR ≥60 mL/min/1.73m2). In other words, among patients with atrial fibrillation commencing warfarin therapy, for every X number of patients with chronic kidney disease (defined as eGFR <60 mL/min/1.73m2), 1 patient would experience a major bleeding event, compared to patients without chronic kidney disease. In this context, this allows the assessment of the impact of the presence of CKD on the risk of bleeding in atrial fibrillation patients commencing warfarin therapy when estimating absolute measures of treatment effects which are clinically meaningful. The substantial difference in the number needed to treat to harm during the first 30 days of warfarin therapy as compared with the period after, highlights the need to consider the bleeding risk relative to kidney function particularly in the period shortly after warfarin treatment commencement. We do, however, acknowledge that when assessing the number needed to treat to harm in this way, this increased risk of major bleeding with worsening kidney function in patients commencing warfarin therapy should be balanced against the risk of stroke according to chronic kidney disease status. However, based on the rationale described above, our approach was to specifically focus on the safety of warfarin therapy in new users of warfarin.
As the author has correctly pointed out, we do not (and cannot), based on our current data, assert that warfarin “causes” major bleeding in patients with chronic kidney disease and atrial fibrillation. Ultimately, to postulate a causal relationship between warfarin therapy and clinical outcomes in patients with atrial fibrillation (by different levels of kidney function), we agree that the risk of stroke and major bleeding need to be assessed in both the warfarin-exposed and unexposed groups, an assessment that should ideally be made within a randomized controlled trial. Observational studies on pharmacoepidemiology which address potential biases involved in these study types including confounding by indication and immortal time bias can also be considered, however, this was beyond the scope of our current study.
Competing interests: No competing interests